Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall

Sweetgreen (SG) stock surges on revenue beat

Sweetgreen (NYSE: SG) stock surged 39% Friday, based on its latest results, which saw it top quarterly revenue expectations.

The company posted a loss per share of ($0.23), $0.05 worse than the analyst estimate of ($0.18). However, revenue for the quarter came in at $157.9 million, rising 26% year-on-year and beating the consensus estimate of $151.61... More

NVIDIA (NVDA) PT Raised to $1,350 at HSBC, 'NVL36/NVL72 server rack pricing power major driver in 2025'

HSBC analyst Frank Lee raised the price target on NVIDIA (NASDAQ: NVDA) to $1,350.00 (from $1,050.00) while maintaining a Buy rating.

The analyst comments "Nvidias NVL36/NVL72 server rack pricing power major driver in 2025: We believe Nvidia will continue to demonstrate its strong pricing power via its NVL36/NVL72 server rack... More

SoundHound AI (SOUN) stock jumps on strong subscription demand in Q1

SoundHound AI (NASDAQ: SOUN) shares jumped Friday on the back of its latest quarterly results, which saw it top earnings estimates.

The company's loss per share for the first quarter was ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $11.86 million.

Revenue grew 73% year-on-year (YoY),... More

Moderna (MRNA) says FDA delaying decision on RSV vaccine approval, shares fall

Moderna (NASDAQ: MRNA) shares are down just over 1% in early Friday trading after the company said the FDA has informed it that it will not be able to meet the May 12 PDUFA for their RSV vaccine due to "administrative... More

JPMorgan Upgrades Novavax (NVAX) to Neutral, 'Sanofi Licensing Deal Brings In Flu Heavy Weight and Lifts Going Concern'

JPMorgan analyst Eric Joseph upgraded Novavax (NASDAQ: NVAX) from Underweight to Neutral.

The analyst comments "On the back of the announced licensing deal with Sanofi, we are upgrading Novavax shares to Neutral from Underweight. With the injection of cash upfront ($500M) removing Novavaxs going concern, , and the greater commercial heft brought to both COVID... More